NCT06011291RecruitingPhase 1
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYH2051 Monotherapy in Patients With Advanced Solid Tumors or in Combination With Radiotherapy in Patients With Locally Advanced Head and Neck Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.1 site in 1 country73 target enrollmentStarted: August 15, 2023Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 73
- Locations
- 1
- Primary Endpoint
- Incidence of dose-limiting toxicities (DLTs)
Study Overview
Brief Summary
This is an open-label, multicenter, dose-escalation phase I study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor efficacy of SYH2051 in patients with advanced solid tumors or in combination with radiotherapy (RT) in patients with locally advanced head and neck cancer.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥18 years old, male or female;
- •Phase Ia: Patients with histologically or cytologically confirmed advanced solid tumors, for whom there is no standard therapy available, or ineffective or intolerant to standard therapy. Phase Ib/Ic: Patients with histologically or cytologically confirmed locally advanced head and neck cancer suitable for radiotherapy alone;
- •Eastern Collaborative Oncology Group (ECOG) Performance Status of 0~1;
- •Patients in medical conditions to be able to receive radiotherapy (for phase Ib/Ic);
- •Life expectancy of >3 months;
- •At least one measurable lesion (excluding patients in phase Ic combined with adjuvant radiotherapy);
- •Patients with adequate hematologic, hepatic, renal and coagulation function;
- •Patients are not pregnant or lactating and required contraception;
- •Patients who are willing to provide written informed consent form (ICF) before the beginning of the study.
Exclusion Criteria
- •Any antineoplastic therapy such as chemotherapy, biologic therapy, endocrine therapy, or immunotherapy within 4 weeks before the first dose of the study drug (or within 5 half-lives of other unmarketed study drugs, whichever is longer), except for the following:
- •6 weeks for Nitrosoureas or mitomycin C;
- •2 weeks or five half-lives (whichever is longer) for oral fluorouracil and small molecule targeted drugs;
- •2 weeks for Chinese herbal medicine with antineoplastic indications;
- •Patients with previous (within 2 years before screening) or concurrent other malignancies (only for phase Ib/Ic);
- •Patients had undergone major organ surgery (excluding needle biopsies) within 4 weeks before the first dose, with obvious trauma, or require elective surgery during the study;
- •Severe, non-healing fractures within 4 weeks before the first dose of the study drug;
- •The adverse reactions of previous antineoplastic therapy have not recovered to ≤grade 1 as determined by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria;
- •Patients who had received treatment with any drug that is a medium or strong inhibitor or inducer of cytochrome P450 (CYP) 3A4/5 enzyme activity within 2 weeks before screening or need to continue receiving such drugs;
- •Active brain metastases and/or carcinomatous meningitis;
- •Concurrent serious and/or uncontrolled medical conditions at screening (e.g., severe chronic obstructive pulmonary disease);
- •Patients with abnormal thyroid function were not allowed, except those with euthyroid function after drug control;
- •History of severe cardiovascular disease;
- •History of myopathy or raised creatine kinase (CK) >5 times the upper limit of normal (ULN);
- •Known hypersensitivity or intolerance to any component of the study drug or its excipients;
- •History of autoimmune disease, immunodeficiency disease, including HIV testing positive or other acquired, congenital immunodeficiency diseases, or organ transplantation;
- •Active hepatitis B virus, hepatitis C virus or active syphilis infection;
- •Active dysphagia, malabsorption or other chronic gastrointestinal diseases or conditions that may hamper compliance and/or absorption of the study drug;
- •Other ineligibilities according to the investigator.
Arms & Interventions
Arm A: SYH2051 monotherapy dose escalation in advanced solid tumors (Phase Ia)
Experimental
Intervention: SYH2051 tablets (Drug)
Arm B: SYH2051+RT dose escalation in locally advanced head and neck cancer (Phase Ib)
Experimental
Intervention: SYH2051 tablets (Drug)
Arm B: SYH2051+RT dose escalation in locally advanced head and neck cancer (Phase Ib)
Experimental
Intervention: Intensity-Modulated Radiation Therapy (IMRT) (Radiation)
Arm C: SYH2051+RT dose expansion in locally advanced head and neck cancer (Phase Ic)
Experimental
Intervention: SYH2051 tablets (Drug)
Arm C: SYH2051+RT dose expansion in locally advanced head and neck cancer (Phase Ic)
Experimental
Intervention: Intensity-Modulated Radiation Therapy (IMRT) (Radiation)
Outcomes
Primary Outcomes
Incidence of dose-limiting toxicities (DLTs)
Time Frame: 31 days for Arm A and 11 weeks for Arm B
Recommended phase 2 dose (RP2D) of SYH2051 in combination with RT
Time Frame: 2 years
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Time Frame: 2 years
Maximum tolerated dose (MTD)(if any) or maximum administrated dose (MAD)
Time Frame: up to 1 year
Secondary Outcomes
- Phase Ia: Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf)(1 years)
- Disease Control Rate (DCR)(2 years)
- Phase Ia: Maximum Plasma Concentration (Cmax)(1 years)
- Phase Ia: Time to Maximum Plasma Concentration (Tmax)(1 years)
- Objective response rate (ORR)(2 years)
- Phase Ia: Area under the plasma concentration-time curve from time zero to time of last measurable concentration(AUC0-last)(1 years)
- Duration of locoregional control (DoLC)(2 years)
- Phase Ib and Ic: Concentrations of SYH2051(2 years)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 1
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS SyndromePOEMS SyndromeNCT06518876Novatim Immune Therapeutics (Zhejiang) Co., Ltd.21
Completed
Phase 1
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced MalignanciesSolid Tumor, Unspecified, AdultNCT03628677Arcus Biosciences, Inc.75
Recruiting
Phase 1
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMMLMyelodysplastic SyndromesChronic Myelomonocytic LeukemiaAcute Myeloid LeukemiaNCT05641259Guangzhou Lupeng Pharmaceutical Company LTD.198
Unknown
Phase 1
MAX-10181 in Patients With Advanced Solid TumorSolid TumorNCT05196360Maxinovel Pty., Ltd.80
Completed
Phase 1
A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck CancerSquamous Cell Carcinoma of the Head and NeckNCT02262741MedImmune LLC71